Vatelizumab是一种靶向Integrin α2β1(very late antigen 2,VLA-2，CD49b)的人源化单克隆抗体，能够通过p38 MAPK信号来增强调节性T细胞的频率，可用于研究多发性硬化症。

Zelavespib HCl是一种新型Hsp90抑制剂，是一种新型嘌呤基类似物，也是一种可能是CIRT的一种有前途的放射增敏剂。Zelavespib HCl 在许多恶性肿瘤临床前模型中显示出抗肿瘤活性。Zelavespib HCl对 Rad51 和Ku70 的蛋白表达水平有抑制作用，这可能与双链断裂修复的同源重组途径和非同源末端连接途径有关。

Nyasol may have potential to be developed as medicines for the treatment of allergies by inhibiting the activation of mast cells. Nyasol shows anti-inflammatory properties by inhibiting iNOS expression; it also has antifungal activity, it is significantly

para-Nitroblebbistatin 是无细胞毒性、无荧光、光稳定、特异性的肌球蛋白 II (Myosin II) 抑制剂。para-Nitroblebbistatin 可用于肌球蛋白 II 在生理学、发育和细胞生物学中特殊作用的相关研究。

Ellipticine quinone, also known as NSC-383230, is a Drp1 inhibitor. rpitor1 and Drpitor1a inhibited the GTPase activity of Drp1 without inhibiting the GTPase of dynamin 1. Ellipticine quinone showed greater potency than the current std. Drp1 GTPase inhibitor, mdivi-​1, (IC50 for mitochondrial fragmentation are (0.06, and 10 μM, resp.)​. Ellipticine quinone suppressed lung cancer tumor growth in a mouse xenograft model. Ellipticine quinone also inhibited mitochondrial ROS prodn., prevented mitochondrial fission, and improved right ventricular diastolic dysfunction during IR injury.

E7820 (ER68203-00) 是具有口服活性芳香族磺酰胺衍生物，是一种血管生成抑制剂，可抑制内皮上整合素 α2 亚基的表达。它调节 α1，α2，α3 和 α5 整联素 mRNA 表达，具有抗血管生成和抗肿瘤活性。它抑制大鼠主动脉血管生成，IC50为 0.11 μg/ml。